From Sensitivity to Reliability: Clinical-Grade cfDNA Controls for Liquid Biopsy

In this Ask the Expert, Björn Nowack, co-founder and managing director of SensID, discusses how clinical-grade cfDNA reference materials are transforming liquid biopsy validation and supporting the next generation of ctDNA assay development. Learn how patient-like, low-noise reference standards improve detection sensitivity, reduce background interference, and enable laboratories to confidently identify low-frequency variants essential for early cancer detection and monitoring.

Emerging FDA-compliant molecular diagnostics guidance influences assay design, and manufacturers can align their validation processes with evolving regulatory expectations. Nowack highlights the growing importance of precision medicine quality controls in bridging research innovation and clinical practice, and how reproducible materials accelerate next-generation sequencing reference standards for oncology and beyond.

Whether you work in molecular diagnostics, clinical research, or lab management, get a glimpse of actionable insights on how advanced reference materials strengthen data integrity and streamline regulatory readiness. Read now to see how these innovations are setting new benchmarks for accuracy, compliance, and confidence in precision medicine.